Quantitative evaluation of the efficacy and safety of first-line systemic therapies for advanced hepatocellular carcinoma
GastroenterologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- European journal of clinical pharmacology
- Publicado em
- 28 dez 2024
- Citações
- 2
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Quantitative evaluation of the efficacy and safety of first-line systemic therapies for advanced hepatocellular carcinoma
Xinrui Wang, Jihan Huang, Yixiao Liu, Lijuan Wu, Ruifen Cai, Qingshan Zheng, Lujin Li
Descritores MeSH
- Liver Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- Carcinoma, Hepatocellular
- Antineoplastic Agents
- Monte Carlo Method
- Treatment Outcome
- Sorafenib
- Angiogenesis Inhibitors
- Progression-Free Survival
- Immune Checkpoint Inhibitors
Veja também
Estudos relacionados
- Is PD-1/PD-L1 inhibitor plus bevacizumab superior to sorafenib as first-line treatment for advanced hepatocellular carcinoma? A pooled analysis of four phase 3 RCTs
- Hepatic arterial infusion chemotherapy (HAlC) versus sorafenib for hepatocellular carcinoma (HCC) in Barcelona Clinic Liver Cancer (BCLC) B/C: A systematic review and meta-analysis
- First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular carcinoma: a meta-analysis of phase 3 trials
- Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis